Mirae Asset Global Investments Co. Ltd. Sells 256 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Mirae Asset Global Investments Co. Ltd. decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,077 shares of the biopharmaceutical company’s stock after selling 256 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $134,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Alkeon Capital Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 34.3% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after buying an additional 769,884 shares during the period. Baker BROS. Advisors LP boosted its holdings in Ultragenyx Pharmaceutical by 7.5% in the third quarter. Baker BROS. Advisors LP now owns 1,576,114 shares of the biopharmaceutical company’s stock worth $87,553,000 after acquiring an additional 109,567 shares in the last quarter. Geode Capital Management LLC grew its stake in Ultragenyx Pharmaceutical by 4.4% in the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company’s stock valued at $87,296,000 after acquiring an additional 65,623 shares during the period. Two Sigma Advisers LP increased its holdings in shares of Ultragenyx Pharmaceutical by 123.4% during the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock valued at $54,872,000 after acquiring an additional 545,600 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of Ultragenyx Pharmaceutical by 35.9% during the third quarter. Point72 Asset Management L.P. now owns 653,660 shares of the biopharmaceutical company’s stock worth $36,311,000 after purchasing an additional 172,711 shares during the period. Institutional investors own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Up 0.2 %

Shares of NASDAQ:RARE opened at $43.52 on Friday. The firm has a fifty day simple moving average of $43.81 and a two-hundred day simple moving average of $49.59. The stock has a market capitalization of $4.02 billion, a P/E ratio of -6.73 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RARE shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Piper Sandler upped their target price on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, January 13th. Wells Fargo & Company increased their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, December 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.